Key result
Elevated soluble CD146 emerges as a potential diagnostic biomarker for cardiovascular and inflammatory diseases.
Why the study?
Soluble CD146 has been widely studied for its physiological roles and involvement in pathologic angiogenesis and inflammatory diseases, but its significance in disease diagnosis and treatment requires summarization.
This review highlights the potential of soluble CD146 as a biomarker for disease diagnosis and prognosis, particularly in conditions involving pathologic angiogenesis and inflammation.
May support soluble CD146 as a biomarker in angiogenesis-related disease; leaves open cardiovascular validation in prospective studies.
Soluble CD146 (sCD146), which is different from membrane CD146, exists in serum and histological fluids of humans. Since first reported in 1998, sCD146 has been widely studied. The results show that it plays a variety of physiological roles in the human body and is involved in pathologic angiogenesis and inflammatory diseases. Recently, sCD146 is shown to be an indicator for the diagnosis and prognosis of several diseases. Here we summarize the research on sCD146 in the last 20 years, with a particular focus on the significance of sCD146 in disease diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted a review in Various diseases (autoimmune, inflammatory, cardiovascular, tumors). Soluble CD146 was evaluated. Soluble CD146 is elevated in various pathological conditions, including autoimmune, inflammatory, and cardiovascular diseases, and serves as a potential biomarker for disease diagnosis and a target for tumor therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: